Psoriasis

Due to the multimorbid nature of the disease, clinicians must screen, monitor, and aggressively treat the associated comorbidities.

More research is needed to understand the pathogenesis underlying this association.

The International Psoriasis Council (IPC)’s new binary classification system aims to streamline access to systemic treatments for patients who previously were likely undertreated.

UCB announced that more than 90% of patients treated with bimekizumab have maintained IGA 1/0 results in their long-term BE BRIGHT trial.

The FDA has accepted the New Drug Application (NDA) for tapinarof as a treatment for plaque psoriasis in adults and set the PDUFA target action date to Q2 2022.

Mark Lebwohl, MD, explains the recent delay in approval of JAK inhibitors by the FDA, how it is affecting the inflammatory skin disease community, and if physicians should be concerned.

In this video interview, Jerry Bagel, MD, MS, discusses improvement in quality of life for pediatric psoriasis patients and current and emerging treatments.

As COVID-19 eases, the FDA is breaking through its backlog and clinical trials are moving forward, opening the way for a new wave of treatments.

Amgen and the International Federation of Psoriasis Associations have announced their efforts to combat the challenges of psoriasis.

BFI-751, Biofactura’s biosimilar drug to ustekinumab will be investigated for the first time on human patients.

Camp Wonder, a camp that supports kids with skin disease and is sponsored by Galderma, is celebrating their 20th year of operations this week.

Gastrointestinal infections were the most common serious infections associated with biologics, according to a cohort analysis.

Addressing underdiagnosis, underrepresentation, and undertreatment in skin of color patients with psoriasis.

Engage patients in treatment compliance and lifestyle changes to achieve optimal outcomes.

Sol-Gel has announced pre-clinical data on SGT-510, its roflumilast drug, for the treatment of psoriasis.

The FDA announces it did not meet the June 25 PDUFA action date on the sNDA for active psoriatic arthritis treatment, upadacitinib.

COSMOS phase 3b study data demonstrated the effectiveness of guselkumab in patients diagnosed with psoriatic arthritis.

The National Psoriasis Foundation has updated its guidance statements for individuals living with psoriatic disease during the COVID-19 pandemic.

The pro-inflammatory transcription factor is critical for the expression of IL-23, which is known to play a role in psoriasis.

Biologic therapy has proven very useful in treating an increasing number of dermatologic diseases and conditions. However, caution is warranted for patients with chronic infectious diseases.

John Browning, MD, FAAD, FAAP, MBA, discusses the impact of the recent FDA approval of secukinumab (Cosentyx, Novartis) for the treatment of moderate to severe plaque psoriasis in children and adolescents.

Dermavant has submitted a New Drug Application (NDA) to the FDA seeking approval for its novel topical for the treatment of mild, moderate, and severe plaque psoriasis in adult patients.

Secukinumab (Cosentyx, Novartis) has received FDA approval for the treatment of children and adolescents with moderate to severe plaque psoriasis.

AxisBiotix-Ps food supplement shows positive results in a recent consumer study evaluating its efficacy for psoriasis treatment.

Thanks to targeted drugs in early-stage development, patients with generalized pustular psoriasis (GPP) will one day likely have FDA-approved treatments for the disease, according to one expert.